NASDAQ:SPPI Spectrum Pharmaceuticals (SPPI) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.03▼$1.0350-Day Range$0.94▼$1.0352-Week Range$0.32▼$1.57VolumeN/AAverage Volume1.93 million shsMarket Capitalization$211.41 millionP/E RatioN/ADividend YieldN/APrice Target$2.44 ProfileProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Spectrum Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside136.7% Upside$2.44 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.14) to $0.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.87 out of 5 starsMedical Sector752nd out of 970 stocksPharmaceutical Preparations Industry361st out of 456 stocks 3.0 Analyst's Opinion Consensus RatingSpectrum Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.44, Spectrum Pharmaceuticals has a forecasted upside of 136.7% from its current price of $1.03.Amount of Analyst CoverageSpectrum Pharmaceuticals has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for SPPI. Previous Next 0.0 Dividend Strength Dividend YieldSpectrum Pharmaceuticals does not currently pay a dividend.Dividend GrowthSpectrum Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSpectrum Pharmaceuticals has received a 74.89% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Spectrum Pharmaceuticals is -0.75. Previous Next N/A News and Social Media Coverage Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spectrum Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.70% of the stock of Spectrum Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 21.67% of the stock of Spectrum Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Spectrum Pharmaceuticals are expected to grow in the coming year, from ($0.14) to $0.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spectrum Pharmaceuticals is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spectrum Pharmaceuticals is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpectrum Pharmaceuticals has a P/B Ratio of 6.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Spectrum Pharmaceuticals (NASDAQ:SPPI) StockSpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.Read More SPPI Stock News HeadlinesJuly 24, 2023 | seekingalpha.comBuy Spectrum Pharmaceuticals For Exposure To Assertio HoldingsJuly 8, 2023 | fool.comSpectrum Pharmaceuticals (NASDAQ: SPPI)September 29, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsJuly 3, 2023 | benzinga.comMoore Kuehn Encourages SYNH, SPPI, ARNC and EMBK Investors to Contact Law FirmJune 30, 2023 | finance.yahoo.comSPPI - Spectrum Pharmaceuticals, Inc.May 26, 2023 | msn.comHC Wainwright & Co. Reiterates Spectrum Pharmaceuticals (SPPI) Neutral RecommendationMay 17, 2023 | finance.yahoo.comSpectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementMay 15, 2023 | msn.comJefferies Downgrades Spectrum Pharmaceuticals (SPPI)September 29, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsMay 14, 2023 | finance.yahoo.comNews Flash: Analysts Just Made A Captivating Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ForecastsMay 10, 2023 | finance.yahoo.comQ1 2023 Assertio Holdings Inc Earnings CallMay 9, 2023 | msn.comSpectrum Pharmaceuticals rises as co. says its Q1 net sales up 54% Q/QMay 9, 2023 | finance.yahoo.comSpectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2023 | markets.businessinsider.comB.Riley Financial Remains a Hold on Spectrum Pharmaceuticals (SPPI)May 1, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds SPPI, NATI, CCFN, and ARST Shareholders About Its Ongoing InvestigationsApril 30, 2023 | benzinga.comLifshitz Law PLLC Announces Investigations of HOTH, ASRT, SPPI, and CEIApril 28, 2023 | benzinga.comMoore Kuehn Encourages HOTH, HSKA, SPPI, and GLOP Investors to Contact Law FirmApril 27, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Investigates Spectrum Pharmaceuticals, Inc.April 27, 2023 | benzinga.comSpectrum Pharmaceuticals Stock (NASDAQ:SPPI), Short Interest ReportApril 26, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Spectrum Pharmaceuticals, Inc. BuyoutApril 26, 2023 | markets.businessinsider.comExpert Ratings for Spectrum PharmaApril 26, 2023 | msn.comHC Wainwright & Co. Downgrades Spectrum Pharmaceuticals (SPPI)April 26, 2023 | msn.comJMP Securities Downgrades Spectrum Pharmaceuticals (SPPI)April 26, 2023 | markets.businessinsider.comJMP Securities downgrades Spectrum Pharmaceuticals (SPPI) to a HoldApril 26, 2023 | benzinga.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Spectrum Pharmaceuticals, Inc.April 25, 2023 | marketwatch.comAssertio to Acquire Outstanding Shares of Spectrum PharmaceuticalsApril 25, 2023 | seekingalpha.comAssertio to acquire Spectrum in all stock deal, sending stocks on opposite pathsSee More Headlines Receive SPPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SPPI Company Calendar Last Earnings11/10/2021Today9/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SPPI CUSIP84763A10 CIK831547 Webwww.sppirx.com Phone(617) 586-3900Fax702-260-7405Employees86Year Founded2002Price Target and Rating Average Stock Price Forecast$2.44 High Stock Price Forecast$4.00 Low Stock Price Forecast$0.75 Forecasted Upside/Downside+136.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,400,000.00 Net MarginsN/A Pretax Margin-263.04% Return on Equity-218.44% Return on Assets-66.16% Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.38 Sales & Book Value Annual Sales$10.11 million Price / Sales20.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book6.87Miscellaneous Outstanding Shares205,250,000Free Float199,704,000Market Cap$211.41 million OptionableOptionable Beta2.15 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Thomas J. Riga (Age 48)Pres, CEO & Director Comp: $1.07MMs. Nora E. Brennan (Age 54)Exec. VP & CFO Comp: $46.25kMr. Keith M. McGahan J.D. (Age 47)L.L.M., Exec. VP, Chief Legal Officer & Corp. Sec. Comp: $948.26kMr. Michael A. GrabowExec. VP & Chief Bus. OfficerDr. Lyndah K. Dreiling M.B.A.M.D., Sr. VP of Clinical Devel.Key CompetitorsRigel PharmaceuticalsNASDAQ:RIGLVerastemNASDAQ:VSTMMerrimack PharmaceuticalsNASDAQ:MACKEmergent BioSolutionsNYSE:EBSXOMANASDAQ:XOMAView All CompetitorsInsiders & InstitutionsGTS Securities LLCBought 51,109 shares on 8/16/2023Ownership: 0.025%Alethea Capital Management LLCSold 37,508 shares on 8/15/2023Ownership: 0.366%Beryl Capital Management LLCBought 508,304 shares on 8/15/2023Ownership: 0.248%XTX Topco LtdBought 144,593 shares on 8/15/2023Ownership: 0.070%Citadel Advisors LLCSold 1,900 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SPPI Stock - Frequently Asked Questions Should I buy or sell Spectrum Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SPPI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPPI, but not buy additional shares or sell existing shares. View SPPI analyst ratings or view top-rated stocks. What is Spectrum Pharmaceuticals' stock price forecast for 2023? 5 equities research analysts have issued 12 month target prices for Spectrum Pharmaceuticals' shares. Their SPPI share price forecasts range from $0.75 to $4.00. On average, they anticipate the company's stock price to reach $2.44 in the next year. This suggests a possible upside of 136.7% from the stock's current price. View analysts price targets for SPPI or view top-rated stocks among Wall Street analysts. How were Spectrum Pharmaceuticals' earnings last quarter? Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) released its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.07. During the same quarter in the previous year, the business posted ($0.37) earnings per share. What ETF holds Spectrum Pharmaceuticals' stock ? IQ Merger Arbitrage ETF holds 1,389,760 shares of SPPI stock, representing 0.29% of its portfolio. What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO? 2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Spectrum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE). What is Spectrum Pharmaceuticals' stock symbol? Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI." What is Spectrum Pharmaceuticals' stock price today? One share of SPPI stock can currently be purchased for approximately $1.03. How much money does Spectrum Pharmaceuticals make? Spectrum Pharmaceuticals (NASDAQ:SPPI) has a market capitalization of $211.41 million and generates $10.11 million in revenue each year. The biotechnology company earns $-75,400,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. How can I contact Spectrum Pharmaceuticals? Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The official website for the company is www.sppirx.com. The biotechnology company can be reached via phone at (617) 586-3900, via email at ir@sppirx.com, or via fax at 702-260-7405. This page (NASDAQ:SPPI) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spectrum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.